Identifying marks

Identifying marks: advances in marking, coding, and inspection technology have led to new anticounterfeiting tools for drug makers trying to protect products that are in pill formSolid dosage form manufacturers have long relied on shape and color as well as on-pill imprints of

Get Your Wonder Drugs!

Get Your Wonder Drugs!: But do you know what it takes to produce them? - high costs of drug research and developmentHarry Howard almost made the biggest blunder of his life when he tossed the building blocks of a wonder drug

Generic makers are

Generic makers are seeing promise in field of biotech engineering - Generic drugs: special reportGeneric drug makers are knocking on a door that never has been opened. With a strong undercurrent

Drug Bust: Killing the

Drug Bust: Killing the golden goose - pharmaceutical price controls - Industry OverviewIn an unprecedented series of 60-second radio spots in Michigan last fall, the head of Pfizer's Ann

New supply-chain dynamics: create a distribution services sector; pharmaceutical companies are finally getting the "supply-chain religion" that swept most manufacturing industries in the 1990s. As a result, contract manufacturers will have to operate in a more demanding environment in the future - Outsourcing Outlook

Distribution services are becoming an important part of the pharmaceutical contract services business. Their emergence is not so much the result of


FDA eyes manufacturing innovation to boost drug development: new technologies, along with changes in agency oversight, may provide a critical path to make more new drugs available more quickly to patients

FDA unveiled a report in March that maps out strategies for converting new biomedical discoveries into safe and effective therapies more quickly and


Connecting clinical trial management to pharmaceutical manufacturing - Insight

High research and development costs and lengthy time-to-market challenges make it difficult for pharmaceutical companies to successfully introduce new drugs to market.


Promoting quality in drug manufacturing: FDA is re-engineering the CMC review process for innovator and generic drugs and backing risk-based ICH quality standards

As pharmaceutical manufacturing evolves from an art form to a science-based process, the Food and Drug Administration is eyeing opportunities to translate